Thermo Fisher Scientific Inc. (NYSE:TMO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has been given a consensus recommendation of “Moderate Buy” by the twenty ratings firms that are presently covering the firm, Marketbeat.com reports. Four investment analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $605.30.

Several research firms have recently weighed in on TMO. Stifel Nicolaus reduced their price objective on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating for the company in a research note on Thursday, April 24th. The Goldman Sachs Group set a $610.00 price objective on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating on the stock in a report on Thursday, April 24th. Barclays cut their target price on Thermo Fisher Scientific from $620.00 to $475.00 and set an “equal weight” rating on the stock in a report on Thursday, April 10th. Finally, Evercore ISI dropped their price objective on Thermo Fisher Scientific from $585.00 to $500.00 and set an “outperform” rating on the stock in a research note on Thursday, April 24th.

Thermo Fisher Scientific Trading Up 0.9%

NYSE:TMO opened at $401.99 on Friday. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $420.74 and its two-hundred day moving average is $495.81. Thermo Fisher Scientific has a 52 week low of $390.50 and a 52 week high of $627.88. The company has a market cap of $151.75 billion, a PE ratio of 24.32, a P/E/G ratio of 2.99 and a beta of 0.78.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. The firm had revenue of $10.36 billion for the quarter, compared to analysts’ expectations of $10.23 billion. During the same period last year, the firm earned $5.11 EPS. The firm’s revenue was up .2% compared to the same quarter last year. On average, analysts predict that Thermo Fisher Scientific will post 23.28 EPS for the current year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.43%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.09%.

Insider Buying and Selling

In related news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now owns 23,167 shares of the company’s stock, valued at $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Michael A. Boxer sold 3,775 shares of the company’s stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. This represents a 25.87% decrease in their position. The disclosure for this sale can be found here. 0.33% of the stock is owned by insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Several hedge funds and other institutional investors have recently made changes to their positions in TMO. LaFleur & Godfrey LLC boosted its stake in Thermo Fisher Scientific by 9.1% in the fourth quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company’s stock valued at $15,486,000 after acquiring an additional 2,488 shares during the last quarter. Brighton Jones LLC lifted its stake in shares of Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock valued at $2,293,000 after buying an additional 988 shares in the last quarter. Union Bancaire Privee UBP SA purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter valued at approximately $71,877,000. Revolve Wealth Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares in the last quarter. Finally, Caprock Group LLC lifted its stake in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. Caprock Group LLC now owns 10,062 shares of the medical research company’s stock valued at $5,239,000 after buying an additional 148 shares in the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.